December 18, 202025 min read, 5021 words
Published: December 18, 2020 | 25 min read, 5021 words
Monoclonal antibodies that bind to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) show therapeutic promise but must be produced in mammalian cells and need to be delivered intravenously. By contrast, single-domain antibodies called nanobodies ca...
CRITIC REVIEWS
There don't seem to be any reviews yet.
PUBLIC REVIEWS
There don't seem to be any reviews yet.